Tsolaki M, Makri M, Tsatali M, Teichmann Β
Alzheimer Hellas, Thessaloniki, Greece.
Laboratory of Neurodegenerative diseases, Center for Interdisciplinary Research and Innovation (CIRI-AUTh), Balkan Center, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Adv Exp Med Biol. 2023;1425:609-618. doi: 10.1007/978-3-031-31986-0_59.
As we all know there is no treatment that can stop or delay the progression of dementia. The treatment we use is only symptomatic. EFNS (European Federation of Neurological Societies) recommendations for dementia prevention by Sorbi et al. (2012) concluded that there is no treatment, no lifestyle, which could have an effect on prevention or delay of onset of different forms of dementia until today. The future studies in prevention must recruit younger people, larger sample, and for longer period. The last 10 years we have run, in collaboration with organizations in different European countries, many projects in order to support patients with neurodegenerative diseases, mainly patients with dementia and their caregivers. The first project was a 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease (AD) in Europe: predictors of discontinuation and switch in the ICTUS (Impact of Cholinergic Treatment USe) study, an FP5 project with 1380 patients. Five studies were published. The second project was DESCRIPA study, an FP5 project to DEvelopment of Screening guidelines and clinical CRIteria for Predementia Alzheimer's disease, with 881 patients with mild cognitive impairment (MCI). LLM (Long Lasting Memories) and VRADA (A virtual reality application for the exercise of dementia and Alzheimer patients) are two projects that include body and cognitive exercise for health for the elderly and patients with mild cognitive impairment. The next is the RECAGE (REspectful Caring for the AGitated Elderly) project (Horizon 2020), a prospective cohort study for coping with behavioral and psychological symptoms of dementia. With six European universities we finished a very interesting FP6 project, the AddNeuroMed one, which gives even now information about the progression of normal elderly MCI and AD patients, in collaboration with other consortia. A very interesting Innovative Medicines Initiative (IMI) project about digital biomarkers was entitled Remote Assessment of Disease and Relapse-Alzheimer's Disease (RADAR project). The main goal of this project was the development and validation of technology-enabled, quantitative and sensitive measures of functional decline in people with early-stage AD. A running project is an Erasmus+ one in the higher education field, "Genetic counseling in European universities: The case of neurodegenerative diseases" (GECONEU project). The target of this study is to develop an online course for university students focusing on genetic counseling, and support people and society to better understand the aims of genetic testing and the usefulness of genetic counseling by involving students in an innovative learning and teaching setting. AD-gaming, BRIDGE, iCONNECT (Intergenerational CONtact between studeNts and people with dEmentia through CreaTive education), E.L.So.M.C.I (English Lessons with the Use of Songs for People with Mild Cognitive Impairment), Games4CoSkills, and De-Sign are all Erasmus+ projects that aim to improve the quality of life of patients with MCI or dementia. Story2remember, Dementia right, ASPAD (Augmentation of the Support of Patients suffering from Alzheimer's Disease and their caregivers), INFOCARE (Supporting Informal Caregivers of People with Dementia), S.IN.CA.L.A (Supporting Informal Carers: A Whole-Family and Life course Approach), and PIA (Peer support workers as an Innovative force in Advocacy in dementia care) are all Erasmus+ projects for training and supporting caregivers of patients with dementia.
众所周知,目前尚无能够阻止或延缓痴呆症进展的治疗方法。我们所采用的治疗仅为对症治疗。欧洲神经科学学会联合会(EFNS)由索尔比等人(2012年)提出的痴呆症预防建议得出结论,直至今日,尚无任何治疗方法或生活方式能够对不同形式痴呆症的预防或发病延迟产生影响。未来的预防研究必须招募更年轻的人群、更大的样本,并持续更长时间。在过去十年中,我们与欧洲不同国家的组织合作开展了许多项目,以支持神经退行性疾病患者,主要是痴呆症患者及其护理人员。第一个项目是一项为期两年的前瞻性队列研究,研究欧洲轻度至中度阿尔茨海默病(AD)患者抗痴呆药物的持续性:ICTUS(胆碱能治疗使用的影响)研究中的停药和换药预测因素,这是一个第五框架计划(FP5)项目,涉及1380名患者。该研究发表了五项研究成果。第二个项目是DESCRIPA研究,这是一个FP5项目,旨在制定痴呆前阿尔茨海默病的筛查指南和临床标准,研究对象为881名轻度认知障碍(MCI)患者。LLM(持久记忆)和VRADA(一种用于痴呆症和阿尔茨海默病患者锻炼的虚拟现实应用程序)是两个项目,包括针对老年人和轻度认知障碍患者的身体和认知健康锻炼。接下来是RECAGE(关爱躁动老年人)项目(地平线2020计划),这是一项前瞻性队列研究,旨在应对痴呆症的行为和心理症状。我们与六所欧洲大学共同完成了一个非常有趣的第六框架计划(FP6)项目,即AddNeuroMed项目,该项目与其他联盟合作,目前仍在提供有关正常老年人、MCI患者和AD患者病情进展的信息。一个非常有趣的创新药物计划(IMI)项目,关于数字生物标志物,名为疾病和复发远程评估 - 阿尔茨海默病(RADAR项目)。该项目的主要目标是开发和验证针对早期AD患者功能衰退的技术支持、定量且敏感的测量方法。一个正在进行的项目是高等教育领域的伊拉斯谟+项目,“欧洲大学的遗传咨询:神经退行性疾病案例”(GECONEU项目)。本研究的目标是为大学生开发一门专注于遗传咨询的在线课程,并通过让学生参与创新的学习和教学环境,帮助人们和社会更好地理解基因检测的目的以及遗传咨询的作用。AD - 游戏、BRIDGE、iCONNECT(通过创意教育实现学生与痴呆症患者的代际接触)、E.L.So.M.C.I(为轻度认知障碍患者使用歌曲进行英语教学)、Games4CoSkills和De - Sign都是伊拉斯谟+项目,旨在提高MCI或痴呆症患者的生活质量。Story2remember、Dementia right、ASPAD(增强阿尔茨海默病患者及其护理人员的支持)、INFOCARE(支持痴呆症患者的非正式护理人员)、S.IN.CA.L.A(支持非正式护理人员:全家庭和生命历程方法)以及PIA(同伴支持工作者作为痴呆症护理倡导的创新力量)都是伊拉斯谟+项目,用于培训和支持痴呆症患者的护理人员。